Principal Investigator
Richard Preston
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20210758
Clinical Trial Summary
A Phase I, single-dose, open-label, parallel-group study to assess the pharmacokinetics, safety, and tolerability of FIA586 in participants with mild and moderate hepatic impairment compared to matched healthy participants
Protocol CFIA586A02101
Phase
Phase I
Funding Agency/Sponsor
Industry
Disease
Other